Cargando…

Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: A prospective test negative case–control study

BACKGROUND: Whilst other studies have reported the effectiveness of mRNA vaccination against hospitalisation, including emergency department or intensive care admission, few have assessed effectiveness against other more clinically robust indices of COVID-19 severity. METHODS: A prospective single-c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatzilena, Anastasia, Hyams, Catherine, Challen, Rob, Marlow, Robin, King, Jade, Adegbite, David, Kinney, Jane, Clout, Madeleine, Maskell, Nick, Oliver, Jennifer, Danon, Leon, Finn, Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728025/ https://www.ncbi.nlm.nih.gov/pubmed/36506791 http://dx.doi.org/10.1016/j.lanepe.2022.100552

Ejemplares similares

Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom
por: Hyams, Catherine, et al.
Publicado: (2022)

Effect of COVID-19 Delta (B.1.617.2) and Omicron (B.1.1.529) surges on emergency medicine physician compassion
por: Bowling, John M., et al.
Publicado: (2022)

BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages
por: Jahrsdörfer, Bernd, et al.
Publicado: (2022)

SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era
por: Khemiri, Haifa, et al.
Publicado: (2022)

Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals
por: Leiner, Johannes, et al.
Publicado: (2022)

Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study
por: Ward, Isobel L, et al.
Publicado: (2022)

Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England
por: Allen, Hester, et al.
Publicado: (2023)

Relationships between COVID-19 healthcare outcomes and county characteristics in the U.S. for Delta (B.1.617.2) and Omicron (B.1.1.529 and BA.1.1) variants
por: Bruckhaus, Alexander A., et al.
Publicado: (2023)

Comparative symptomatology of infection with SARS-CoV-2 variants Omicron (B.1.1.529) and Delta (B.1.617.2) from routine contact tracing data in England
por: Ekroth, Alice K. E., et al.
Publicado: (2022)

Differences in Immunological Evasion of the Delta (B.1.617.2) and Omicron (B.1.1.529) SARS-CoV-2 Variants: A Retrospective Study on the Veneto Region’s Population
por: Cocchio, Silvia, et al.
Publicado: (2022)

Comparison of the clinical characteristics of SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) infected patients from a single hospitalist service
por: Radhakrishnan, N., et al.
Publicado: (2023)

Is Omicron really mild? – Comparative analysis of comorbidities and disease outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants
por: Manchanda, Vikas, et al.
Publicado: (2023)

COVID-19 outbreak trends in South Africa: A comparison of Omicron (B.1.1.529), Delta (B.1.617.2), and Beta (B.1.351) variants outbreak periods
por: Al Hasan, Syed Mahfuz, et al.
Publicado: (2022)

Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022
por: Lambrou, Anastasia S., et al.
Publicado: (2022)

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
por: Nyberg, Tommy, et al.
Publicado: (2022)

429. Risk of COVID-19 Related Deaths for SARS-CoV-2 Omicron (B.1.1.529) Compared With Delta (B.1.617.2): A Retrospective Cohort Study
por: Paulson, Shon, et al.
Publicado: (2023)

Outcomes of Monoclonal Antibody Infusion Treatment During Delta (B.1.617.2) and Omicron (B.1.1.529) COVID 19 Variant Surges among Vaccinated and Unvaccinated Patients
por: Ghazanfar, Haider, et al.
Publicado: (2022)

Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom, 2022
por: Chatzilena, Anastasia, et al.
Publicado: (2023)

Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2
por: Wang, Meng, et al.
Publicado: (2023)

Analysis of seven SARS-CoV-2 rapid antigen tests in detecting omicron (B.1.1.529) versus delta (B.1.617.2) using cell culture supernatants and clinical specimens
por: Jungnick, Sabrina, et al.
Publicado: (2022)

Computed Tomographic Imaging Features of COVID-19 Pneumonia Caused by the Delta (B.1.617.2) and Omicron (B.1.1.529) Variant in a German Nested Cohort Pilot Study Group
por: Askani, Esther, et al.
Publicado: (2022)

309. Genetic Diversity and Conservation of Envelope Gene of SARS-CoV-2 and its Variants B.1.1.7, B.1.351, P.1, B.1.617.2 and B.1.1.529 with comparison with other human coronaviruses
por: Liu, Benjamin
Publicado: (2022)

Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants
por: Nörz, Dominik, et al.
Publicado: (2022)

SARS-CoV-2 B.1.1.529 (Omicron) Variant Causes an Unprecedented Surge in Children Hospitalizations and Distinct Clinical Presentation Compared to the SARS-CoV-2 B.1.617.2 (Delta) Variant
por: Taytard, Jessica, et al.
Publicado: (2022)

Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants
por: Selvavinayagam, Sivaprakasam T., et al.
Publicado: (2022)

Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients
por: Benning, Louise, et al.
Publicado: (2022)

mRNA vaccine effectiveness against SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant transmission from home care cases to household contacts in South Korea
por: Park, Hanul, et al.
Publicado: (2022)

The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines
por: Yang, Xinyi, et al.
Publicado: (2022)

Genetic emergence of B.1.617.2 in COVID-19
por: Kirola, L.
Publicado: (2021)

Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants
por: Xu, Xuesong, et al.
Publicado: (2022)

Performance of 20 rapid antigen detection tests to detect SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants using a clinical specimen panel from January 2022, Berlin, Germany
por: Puyskens, Andreas, et al.
Publicado: (2023)

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
por: Wall, Emma C, et al.
Publicado: (2021)

Analysis of the Delta Variant B.1.617.2 COVID-19
por: Shiehzadegan, Shayan, et al.
Publicado: (2021)

Genome Sequences of the Delta Variant (B.1.617.2) and the Kappa Variant (B.1.617.1) Detected in Morocco
por: Melloul, Marouane, et al.
Publicado: (2021)

Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?
por: Chavda, Vivek P, et al.
Publicado: (2022)

SARS-CoV-2 Omicron (B.1.1.529) Variant: No Time to Wait!
por: Rahmani, Shayan, et al.
Publicado: (2022)

Review of concerned SARS-CoV-2 variants like Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529), as well as novel methods for reducing and inactivating SARS-CoV-2 mutants in wastewater treatment facilities
por: Zahmatkesh, Sasan, et al.
Publicado: (2022)

Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study
por: Skarbinski, Jacek, et al.
Publicado: (2022)

Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance
por: Chen, Jiahui, et al.
Publicado: (2021)

The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
por: Paton, Robert S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lav0ahrmjljcjutfbtjt5bnoqu